Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Immunotherapy for Lung Cancer, Part 1: Podcast by Dr. Govindan on MAGE-A3, Stimuvax, and Lucanix
Author
Howard (Jack) West, MD

Here's part 1 of the podcast with Dr. Ramaswamy Govindan from Washington University, in St. Louis, and Dr. Julie Brahmer from Johns Hopkins University in Baltimore, splitting the big topic of new developments in immunotherapy for lung cancer. Though the field has a lot of intuitive appeal, harnessing the body's own immune system to fight cancer with the hope of sustained effect and a very mild side effect profile, proven benefits of immunotherapy in cancer have been slow to come.  But in the last few years, we've seen new treatments with impressive survival benefits in prostate cancer, melanoma, and others...while in lung cancer, the key studies are being conducted but have yet to report out.

Dr. Govindan covered the big topics of MAGE-A3, Stimuvax, and Lucanix in his part of the program.  The audio and video versions of the podcast are below, along with the transcript and figures.

Govindan Immunotherapies in LC Part 1 Audio Podcast

Govindan Immunotherapies for LC Part 1 Transcript

Govindan Immunotherapies in LC Part 1 Figs

 

Part 2, featuring Dr. Brahmer, is being edited now and will be available soon.  This includes some discussion of the research into the anti-PD1 vaccine that emerged as one of the most exciting stories in lung cancer from ASCO 2012, so look for that here soon.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora